ELV earnings

1Q 2026 operating revenue of $49.5 billion, up 1.5% from 1Q 2025 1Q 2026 diluted EPS1 of $8.00; adjusted diluted EPS2 of $12.58 driven by strong operating results and ~$1 per share of non-recurring investment income FY 2026 diluted EPS1 guidance to be at least $19.85, including the Company's estimate of the financial impact for the CMS matter FY 2026 adjusted diluted EPS2 guidance raised to at least $26.75, supported by underlying business strength, actions to reduce medical costs, and increased visibility Reaffirm FY 2026 operating cash flow of at least $5.5 billion, inclusive of potential cash payments for the CMS matter Returned $1.5 billion of capital to shareholders in

Elevance Health (NYSE:ELV) will release first quarter 2026 financial results on April 22, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The call will be available through a live webcast at www.elevancehealth.com under the "Investors" link. You may also acces

4Q 2025 operating revenue of $49.3 billion; FY 2025 of $197.6 billion 4Q 2025 diluted EPS1 of $2.47; adjusted diluted EPS2 of $3.33 FY 2025 diluted EPS1 of $25.21; adjusted diluted EPS2 of $30.29 Projected FY 2026 GAAP diluted EPS1 to be at least $22.30 Projected FY 2026 adjusted diluted EPS2 to be at least $25.50 Returned $4.1 billion of capital to shareholders in 2025 Reaffirming long-term earnings algorithm; recalibrating segment margin targets Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2025 results. "Elevance Health delivered fourth quarter results in line with our outlook, reflecting disciplined execution in a dynamic environment. As

Elevance Health (NYSE:ELV) will release fourth quarter and full year 2025 financial results on January 28, 2026, at 6:00 a.m. Eastern Standard Time ("EST"). Management will review these results and its outlook during a conference call at 8:30 a.m. EST that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 888-566-0046 - No Access Code (Domestic Replay) 203-369-3677 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EST on January 28, 2026, until the end of the day on Februar

Executing with discipline to improve affordability and elevate the member experience 3Q 2025 operating revenue of $50.1 billion, up 12.0% from 3Q 2024 3Q 2025 diluted EPS1 of $5.32; adjusted diluted EPS2 of $6.03 Reaffirm FY 2025 benefit expense ratio and adjusted diluted EPS guidance of approximately 90.0% and approximately $30.00, respectively Returned $3.3 billion of capital to shareholders year-to-date Elevance Health, Inc. (NYSE:ELV) reported third quarter 2025 results. "Our third quarter results were in line with expectations and reflect disciplined execution across Elevance Health. In a dynamic healthcare environment, we're focused on advancing affordability and ele

Elevance Health (NYSE: ELV) will release third quarter 2025 financial results on October 21, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 800-391-9853 - No Access Code (Domestic Replay) 203-369-3269 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on October 21, 2025, until the end of the day on November 21, 2025. Th

2Q 2025 operating revenue of $49.4 billion, up 14.3% from 2Q 2024 2Q 2025 diluted EPS1 of $7.72; adjusted diluted EPS2 of $8.84 Revising FY 2025 adjusted diluted EPS guidance to approximately $30.00 Returned $2.0 billion of capital to shareholders year-to-date Elevance Health, Inc. (NYSE:ELV) reported second quarter 2025 results. "In the second quarter, Elevance Health made meaningful progress in delivering an experience that is simple and personal to those we serve, while advancing our efforts to enhance efficiency across the healthcare system. We are updating our outlook to reflect elevated medical cost trends in ACA and slower rate alignment in Medicaid. While the exter

Elevance Health (NYSE:ELV) will release second quarter 2025 financial results on July 17, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 - Access Code - 3972058 (Domestic) 312-470-0178 - Access Code - 3972058 (International) 866-511-1890 - No Access Code (Domestic Replay) 203-369-1945 - No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on July 17, 2025, until the end of the day on August 15, 2025. The call w

1Q 2025 operating revenue of $48.8 billion, up 15.4% from 1Q 2024 1Q 2025 adjusted operating gain1 of $3.3 billion, up 4.1% from 1Q 2024 1Q 2025 diluted EPS2 of $9.61; adjusted diluted EPS1 of $11.97 Reaffirm FY 2025 adjusted diluted EPS1 of $34.15 to $34.85 Returned $1.3 billion of capital to shareholders in 1Q 2025 Elevance Health, Inc. (NYSE:ELV) reported first quarter 2025 results. "At Elevance Health, our purpose—to improve the health of humanity—drives everything we do. In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces co

Elevance Health (NYSE:ELV) will release first quarter 2025 financial results on April 22, 2025, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-396-1242 – No Access Code (Domestic Replay) 203-369-3272 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on April 22, 2025, until the end of the day on May 22, 2025. The call will als

4Q 2024 operating revenue of $45.0 billion; FY 2024 of $175.2 billion 4Q 2024 diluted EPS1 of $1.81; adjusted diluted EPS2 of $3.84 FY 2024 diluted EPS1 of $25.68; adjusted diluted EPS2 of $33.04 Projected FY 2025 GAAP diluted EPS1 to be in the range of $30.40 to $31.10 Projected FY 2025 adjusted diluted EPS2 to be in the range of $34.15 to $34.85 Quarterly dividend increased by 5% to $1.71 per share Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2024 results. "As part of our commitment to elevating whole health and advancing health beyond healthcare, we deliver value to the members and care providers we serve by ensuring simple, affordable, and

Elevance Health (NYSE:ELV) will release fourth quarter and full year 2024 financial results on January 23, 2025, at 6:00 a.m. Eastern Standard Time ("EST"). Management will review these results and its outlook during a conference call at 8:30 a.m. EST that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 866-405-7292 – No Access Code (Domestic Replay) 203-369-0604 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EST on January 23, 2025, until the end of the day on Februar

3Q 2024 operating revenue of $44.7 billion 3Q 2024 adjusted operating gain1 of $2.4 billion 3Q 2024 diluted EPS2 of $4.36; adjusted diluted EPS1 of $8.37 4Q 2024 dividend of $1.63 per share declared to shareholders Elevance Health, Inc. (NYSE:ELV) reported third quarter 2024 results. "We remain confident in the long-term earnings potential of our diverse businesses as we navigate a dynamic operating environment and unprecedented challenges in the Medicaid business. We expect Medicaid rates will align with the needs of our members in time, and are taking proactive actions to enhance operational efficiencies that will ensure we emerge from this period even stronger." Gail K. Boudre

Elevance Health (NYSE:ELV) will release third quarter 2024 financial results on October 17, 2024, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 866-510-4837 – No Access Code (Domestic Replay) 203-369-1943 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on October 17, 2024, until the end of the day on November 16, 2024. The call

2Q 2024 operating revenue of $43.2 billion 2Q 2024 adjusted operating gain1 of $2.8 billion 2Q 2024 diluted EPS2 of $9.85, up 26%; adjusted diluted EPS1 of $10.12, up 12% 3Q 2024 dividend of $1.63 per share declared to shareholders Elevance Health, Inc. (NYSE:ELV) reported second quarter 2024 results. "Second quarter results reflect the power of our diversified business and thoughtful execution of our strategic initiatives during a dynamic time for our industry, as we remain steadfast in our purpose to improve the health of humanity. We have prudently maintained our full-year outlook and are confident in the earnings power of our Health Benefits and Carelon businesses, which

Elevance Health (NYSE:ELV) will release second quarter 2024 financial results on July 17, 2024, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-391-9851 – No Access Code (Domestic Replay) 203-369-3268 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on July 17, 2024, until the end of the day on August 17, 2024. The call w

1Q 2024 operating revenue of $42.3 billion, up 0.9% from 1Q 2023 1Q 2024 diluted EPS1 of $9.59, up 15.5% from 1Q 2023 and adjusted diluted EPS2 of $10.64, up 12.5% FY 2024 diluted EPS and adjusted diluted EPS guidance raised to greater than $34.05 and $37.20, respectively Launching strategic partnership to advance primary care and physician enablement Elevance Health, Inc. (NYSE:ELV) reported first quarter 2024 results. "First quarter results reflect disciplined execution of our strategic initiatives during a dynamic time for our industry. We are making significant progress expanding Carelon's capabilities, scaling our flywheel for enterprise growth, and delivering results fo

Elevance Health (NYSE:ELV) will release first quarter 2024 financial results on April 18, 2024, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 800-876-4955 – No Access Code (Domestic Replay) 203-369-3997 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on April 18, 2024, until the end of the day on May 17, 2024. The call wil

4Q 2023 operating revenue of $42.5 billion, up 7.0% from 4Q 2022; FY 2023 operating revenue of $170 billion, up 9.3% from FY 2022 4Q 2023 GAAP diluted EPS1 of $3.63, up 1.1% from 4Q 2022 and adjusted diluted EPS2 of $5.62, up 15.2%; FY 2023 GAAP diluted EPS of $25.22, up 3.9% from FY 2022 and adjusted diluted EPS2 of $33.14, up 16.2% Projected FY 2024 GAAP diluted EPS and adjusted diluted EPS2 of greater than $34.29 and $37.10 per share, respectively Quarterly dividend increased by 10.1% to $1.63 per share Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2023 results. "We are pleased to have delivered another year of strong performance in 2023, enabled b

Elevance Health (NYSE:ELV) will release fourth quarter and full year 2023 financial results on January 24, 2024 at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 Access Code - 3972058 (Domestic) 312-470-0178 Access Code - 3972058 (International) 800-568-3942 No Access Code (Domestic Replay) 203-369-3812 No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on January 24, 2024 until the end of the day on February 23, 2024

Third quarter GAAP net income was $5.45 per share, including net negative adjustment items of $3.54 per share. Adjusted net income was $8.99* per share. Operating gain, excluding adjustment items, grew 12.6% year-over-year to $2.5 billion. Operating cash flow was $2.6 billion. Elevance Health, Inc. (NYSE:ELV) reported third quarter 2023 results reflecting strong financial performance across the enterprise. "Elevance Health delivered another quarter of solid performance reflecting the strength and balance of our diversified portfolio of businesses, our continued investments in innovation and growth, and our relentless focus on affordability, simplicity, and customer experience,"

Elevance Health (NYSE:ELV) will release third quarter 2023 financial results on October 18, 2023 at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 (Domestic) 312-470-0178 (International) 866-405-7293 (Domestic Replay) 203-369-0605 (International Replay) The access code for the call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EDT on October 18, 2023 until the end of the day on November 17, 2023. The ca

Second quarter GAAP net income was $7.79 per share, including net negative adjustment items of $1.25 per share. Adjusted net income was $9.04* per share. Operating revenue grew 12.7% year-over-year to $43.4 billion Operating gain grew 12.0% year-over-year to $2.6 billion Medical enrollment increased 938 thousand members year-over-year to 48.0 million members Third quarter 2023 dividend of $1.48 per share declared to shareholders Elevance Health, Inc. (NYSE:ELV) reported second quarter 2023 results reflecting strong financial performance, including double-digit growth in revenue, operating earnings, and adjusted earnings per share. "Our solid execution and continued progres

Elevance Health (NYSE:ELV) will release second quarter 2023 financial results on July 19, 2023, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 (Domestic) 312-470-0178 (International) 800-391-9853 (Domestic Replay) 203-369-3269 (International Replay) The access code for the call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EDT on July 19, 2023 until the end of the day on August 18, 2023. The call wil

First quarter GAAP net income was $8.30 per share, including net negative adjustment items of $1.16 per share. Adjusted net income was $9.46* per share. Operating revenue grew 10.6% year-over-year to $41.9 billion Operating gain grew 16.6% year-over-year to $2.8 billion Medical enrollment increased 1.3 million members year-over-year to 48.1 million members Second quarter 2023 dividend of $1.48 per share declared to shareholders Elevance Health, Inc. (NYSE:ELV) reported first quarter 2023 results reflecting strong financial performance, including double-digit growth in revenue, operating earnings, and adjusted earnings per share. "Elevance Health is off to a strong start in

Elevance Health (NYSE:ELV) will release first quarter 2023 financial results on April 19, 2023, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 (Domestic) 312-470-0178 (International) 866-361-4942 (Domestic Replay) 203-369-0190 (International Replay) The access code for the call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EDT on April 19, 2023 until the end of the day on May 19, 2023. The call will

Fourth quarter and full year GAAP net income was $3.93 and $24.81 per share Fourth quarter and full year adjusted net income was $5.23* and $29.07* per share Full year operating revenue grew 13.7% year-over-year to $156 billion Full year operating gain grew 12.9% year-over-year to $8.5 billion Medical enrollment increased 2.2 million members year-over-year to 47.5 million members Quarterly dividend increased by 16% to $1.48 per share Elevance Health, Inc. (NYSE:ELV) reported fourth quarter and full year 2022 results reflecting strong financial performance, including double-digit growth in revenue, operating earnings, and adjusted earnings per share. "We made considerable progr

Elevance Health (NYSE:ELV) will release fourth quarter 2022 financial results on January 25, 2023, at 6:00 a.m. Eastern Standard Time ("EST"). Management will review these results and its outlook during a conference call at 8:30 a.m. EST that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 (Domestic) 312-470-0178 (International) 800-396-1242 (Domestic Replay) 203-369-3272 (International Replay) The access code for the call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EST on January 25, 2023 until the end of the day on February 24, 2023. The call

Third quarter GAAP net income was $6.68 per share, including net negative adjustment items of $0.85 per share. Adjusted net income was $7.53* per share. Operating revenue grew 11.5% over the prior year quarter to $39.6 billion. Operating gain grew 10.2% over the prior year quarter to $2.3 billion. Medical enrollment increased 2.2 million members year-over-year and 232 thousand members during the quarter to 47.3 million members. Fourth quarter 2022 dividend of $1.28 per share declared to shareholders. Elevance Health, Inc. (NYSE:ELV) reported third quarter 2022 results reflecting strong financial performance, including double-digit growth in revenue, operating earnings, and adjust

Elevance Health (NYSE:ELV) will release third quarter 2022 financial results on October 19, 2022, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 (Domestic) 800-813-5525 (Domestic Replay) 312-470-0178 (International) 203-369-3346 (International Replay) The access code for the call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EDT on October 19, 2022 until the end of the day on November 18, 2022